Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Ribozyme-enhanced single-stranded Ago2-processed interfering RNA triggers efficient gene silencing with fewer off-target effects.

Shang R, Zhang F, Xu B, Xi H, Zhang X, Wang W, Wu L.

Nat Commun. 2015 Oct 12;6:8430. doi: 10.1038/ncomms9430.

2.

Transcription yield of fully 2'-modified RNA can be increased by the addition of thermostabilizing mutations to T7 RNA polymerase mutants.

Meyer AJ, Garry DJ, Hall B, Byrom MM, McDonald HG, Yang X, Yin YW, Ellington AD.

Nucleic Acids Res. 2015 Sep 3;43(15):7480-8. doi: 10.1093/nar/gkv734. Epub 2015 Jul 24.

3.

Molecular Properties, Functional Mechanisms, and Applications of Sliced siRNA.

Sun G, Yeh SY, Yuan CW, Chiu MJ, Yung BS, Yen Y.

Mol Ther Nucleic Acids. 2015 Jan 20;4:e221. doi: 10.1038/mtna.2014.73.

4.

Inhibition of hepatitis C virus in chimeric mice by short synthetic hairpin RNAs: sequence analysis of surviving virus shows added selective pressure of combination therapy.

Dallas A, Ilves H, Ma H, Chin DJ, Maclachlan I, Klumpp K, Johnston BH.

J Virol. 2014 May;88(9):4647-56. doi: 10.1128/JVI.00105-14. Epub 2014 Jan 29.

5.

Current progress on aptamer-targeted oligonucleotide therapeutics.

Dassie JP, Giangrande PH.

Ther Deliv. 2013 Dec;4(12):1527-46. doi: 10.4155/tde.13.118. Review.

6.

Lentiviral vector-mediated RNA silencing in the central nervous system.

Hutson TH, Foster E, Moon LD, Yáñez-Muñoz RJ.

Hum Gene Ther Methods. 2014 Feb;25(1):14-32. doi: 10.1089/hgtb.2013.016. Epub 2013 Nov 1. Review.

7.

Formulated minimal-length synthetic small hairpin RNAs are potent inhibitors of hepatitis C virus in mice with humanized livers.

Ma H, Dallas A, Ilves H, Shorenstein J, MacLachlan I, Klumpp K, Johnston BH.

Gastroenterology. 2014 Jan;146(1):63-6.e5. doi: 10.1053/j.gastro.2013.09.049. Epub 2013 Sep 27.

8.

Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in Mice.

Dallas A, Ilves H, Shorenstein J, Judge A, Spitler R, Contag C, Wong SP, Harbottle RP, Maclachlan I, Johnston BH.

Mol Ther Nucleic Acids. 2013 Sep 17;2:e123. doi: 10.1038/mtna.2013.50.

9.

Tuning response curves for synthetic biology.

Ang J, Harris E, Hussey BJ, Kil R, McMillen DR.

ACS Synth Biol. 2013 Oct 18;2(10):547-67. doi: 10.1021/sb4000564. Epub 2013 Sep 3.

10.

Efficient delivery of RNA interference oligonucleotides to polarized airway epithelia in vitro.

Ramachandran S, Krishnamurthy S, Jacobi AM, Wohlford-Lenane C, Behlke MA, Davidson BL, McCray PB Jr.

Am J Physiol Lung Cell Mol Physiol. 2013 Jul 1;305(1):L23-32. doi: 10.1152/ajplung.00426.2012. Epub 2013 Apr 26.

11.

Development of a 2',4'-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo.

Wada S, Obika S, Shibata MA, Yamamoto T, Nakatani M, Yamaoka T, Torigoe H, Harada-Shiba M.

Mol Ther Nucleic Acids. 2012 Sep 18;1:e45. doi: 10.1038/mtna.2012.32.

12.

Embedding siRNA sequences targeting apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy.

Maczuga P, Lubelski J, van Logtenstein R, Borel F, Blits B, Fakkert E, Costessi A, Butler D, van Deventer S, Petry H, Koornneef A, Konstantinova P.

Mol Ther. 2013 Jan;21(1):217-27. doi: 10.1038/mt.2012.160. Epub 2012 Oct 23.

13.

Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.

Bramsen JB, Kjems J.

Front Genet. 2012 Aug 20;3:154. doi: 10.3389/fgene.2012.00154. eCollection 2012.

14.

Right- and left-loop short shRNAs have distinct and unusual mechanisms of gene silencing.

Dallas A, Ilves H, Ge Q, Kumar P, Shorenstein J, Kazakov SA, Cuellar TL, McManus MT, Behlke MA, Johnston BH.

Nucleic Acids Res. 2012 Oct;40(18):9255-71. doi: 10.1093/nar/gks662. Epub 2012 Jul 18.

15.

Progress toward in vivo use of siRNAs-II.

Rettig GR, Behlke MA.

Mol Ther. 2012 Mar;20(3):483-512. doi: 10.1038/mt.2011.263. Epub 2011 Dec 20. Review.

16.

8-Oxoguanosine switches modulate the activity of alkylated siRNAs by controlling steric effects in the major versus minor grooves.

Kannan A, Fostvedt E, Beal PA, Burrows CJ.

J Am Chem Soc. 2011 Apr 27;133(16):6343-51. doi: 10.1021/ja2003878. Epub 2011 Mar 31.

17.

Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics.

Moore MD, Cookson J, Coventry VK, Sproat B, Rabe L, Cranston RD, McGowan I, James W.

J Biol Chem. 2011 Jan 28;286(4):2526-35. doi: 10.1074/jbc.M110.178426. Epub 2010 Nov 24.

18.

Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity.

Ge Q, Ilves H, Dallas A, Kumar P, Shorenstein J, Kazakov SA, Johnston BH.

RNA. 2010 Jan;16(1):106-17. doi: 10.1261/rna.1894510. Epub 2009 Dec 1.

Supplemental Content

Support Center